- Home
- SKM vs JAZZ Comparison
SKM vs JAZZ Comparison
Compare SKM & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKM
- JAZZ
- Stock Information
- Founded
- SKM 1984
- JAZZ 2003
- Country
- SKM South Korea
- JAZZ Ireland
- Employees
- SKM N/A
- JAZZ N/A
- Industry
- SKM Telecommunications Equipment
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- SKM Telecommunications
- JAZZ Health Care
- Exchange
- SKM Nasdaq
- JAZZ Nasdaq
- Market Cap
- SKM 7.6B
- JAZZ 8.6B
- IPO Year
- SKM 1996
- JAZZ 2007
- Fundamental
- Price
- SKM $20.14
- JAZZ $170.80
- Analyst Decision
- SKM Hold
- JAZZ Strong Buy
- Analyst Count
- SKM 1
- JAZZ 14
- Target Price
- SKM N/A
- JAZZ $181.50
- AVG Volume (30 Days)
- SKM 674.8K
- JAZZ 1.0M
- Earning Date
- SKM 10-30-2025
- JAZZ 11-05-2025
- Dividend Yield
- SKM 4.25%
- JAZZ N/A
- EPS Growth
- SKM N/A
- JAZZ N/A
- EPS
- SKM 1.89
- JAZZ N/A
- Revenue
- SKM $12,327,006,340.00
- JAZZ $4,157,832,999.00
- Revenue This Year
- SKM N/A
- JAZZ $5.80
- Revenue Next Year
- SKM $3.18
- JAZZ $6.06
- P/E Ratio
- SKM $19.47
- JAZZ N/A
- Revenue Growth
- SKM N/A
- JAZZ 4.14
- 52 Week Low
- SKM $19.84
- JAZZ $95.49
- 52 Week High
- SKM $24.34
- JAZZ $172.91
- Technical
- Relative Strength Index (RSI)
- SKM 38.15
- JAZZ 82.88
- Support Level
- SKM $20.20
- JAZZ $128.80
- Resistance Level
- SKM $20.60
- JAZZ $144.97
- Average True Range (ATR)
- SKM 0.23
- JAZZ 5.23
- MACD
- SKM 0.03
- JAZZ 2.17
- Stochastic Oscillator
- SKM 19.49
- JAZZ 95.48
About SKM SK Telecom Co. Ltd.
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.